Skip to main content

Table 3 Summary of AEs

From: Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme

 

Grade 1

Grade 2

Grade 3

Grade 4

Patients with a treatment-related AE, n (%)

21 (28.4)

16 (21.6)

7 (9.5)

1 (1.4)

All events by maximum reported grade, n

Any

68

23

7

1

Pruritus

10

3

  

Diarrhoea

6

4

2

 

Pain

7

2

2

 

Fever

8

1

1

 

Anaemia

6

1

  

Rash

5

2

  

Nausea

6

   

Asthenia

5

   

Cough

2

   

Dyspnoea

1

1

  

Hyperthyroidism

2

   

Hypothyroidism

 

2

  

Infection

 

2

  

Scrotal pain

1

1

  

Dermatitis

 

1

  

Oedema

 

1

  

Epigastric pain

  

1

 

Herpes Zoster

 

1

  

Hypocalcemia

 

1

  

Increase in aspartate transaminase/alanine transaminase

  

1

 

Pancytopenia

   

1

Other*

9

   
  1. * Single AEs of grade 1 intensity: penis bleeding, cephalea, confusion, fatigue, constipation, anorexia, inappetence and dysgeusia, flu-like syndrome, ocular Herpes Zoster with oedema and pain.
  2. AEs adverse events.